标题
Targeted Therapy and Immunotherapy for Melanoma in Japan
作者
关键词
Melanoma, Targeted therapy, Immunotherapy, Acral, Mucosal, Asian
出版物
CURRENT TREATMENT OPTIONS IN ONCOLOGY
Volume 20, Issue 1, Pages -
出版商
Springer Nature
发表日期
2019-01-25
DOI
10.1007/s11864-019-0607-8
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Melanoma: What do all the mutations mean?
- (2018) Elizabeth J. Davis et al. CANCER
- Diagnosis and Management of Acral Lentiginous Melanoma
- (2018) Yoshiyuki Nakamura et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Phase 1/2 study assessing the safety and efficacy of dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation-positive advanced cutaneous melanoma
- (2018) Naoya Yamazaki et al. JOURNAL OF DERMATOLOGY
- Adjuvant vemurafenib in resected, BRAF V600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
- (2018) Michele Maio et al. LANCET ONCOLOGY
- Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
- (2018) Reinhard Dummer et al. LANCET ONCOLOGY
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
- (2018) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006
- (2018) Omid Hamid et al. BRITISH JOURNAL OF CANCER
- Phase Ⅲ randomized, multicenter trial comparing high-dose IFN-a2b with temozolomide plus cisplatin as adjuvant therapy for resected mucosal melanoma.
- (2018) Bin Lian et al. JOURNAL OF CLINICAL ONCOLOGY
- Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial
- (2018) Reinhard Dummer et al. LANCET ONCOLOGY
- Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries
- (2018) L. Kandolf Sekulovic et al. EUROPEAN JOURNAL OF CANCER
- Efficacy and safety of nivolumab in combination with ipilimumab in Japanese patients with advanced melanoma: An open-label, single-arm, multicentre phase II study
- (2018) Kenjiro Namikawa et al. EUROPEAN JOURNAL OF CANCER
- Longer Follow-Up Confirms Relapse-Free Survival Benefit With Adjuvant Dabrafenib Plus Trametinib in Patients With Resected BRAF V600–Mutant Stage III Melanoma
- (2018) Axel Hauschild et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
- (2018) Frank Stephen Hodi et al. LANCET ONCOLOGY
- Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition
- (2017) Markus V. Heppt et al. EUROPEAN JOURNAL OF CANCER
- Safety, tolerability, and pharmacokinetic profile of dabrafenib in Japanese patients with BRAF V600 mutation-positive solid tumors: a phase 1 study
- (2017) Yutaka Fujiwara et al. INVESTIGATIONAL NEW DRUGS
- Randomized phase III trial of adjuvant therapy with locoregional interferon beta versus surgery alone in stage II/III cutaneous melanoma: Japan Clinical Oncology Group Study (JCOG1309, J-FERON)
- (2017) Kenjiro Namikawa et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis
- (2017) Sandra P. D’Angelo et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
- (2017) Jacob Schachter et al. LANCET
- Binimetinib versus dacarbazine in patients with advanced NRAS -mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial
- (2017) Reinhard Dummer et al. LANCET ONCOLOGY
- Characteristics of melanoma in Japan
- (2017) Taro Tomizuka et al. MELANOMA RESEARCH
- Whole-genome landscapes of major melanoma subtypes
- (2017) Nicholas K. Hayward et al. NATURE
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- (2017) Jeffrey Weber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
- (2017) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-PD1 treatment in metastatic uveal melanoma in the Netherlands
- (2016) M. K. van der Kooij et al. ACTA ONCOLOGICA
- Patterns of Clinical Response with Talimogene Laherparepvec (T-VEC) in Patients with Melanoma Treated in the OPTiM Phase III Clinical Trial
- (2016) Robert H. I. Andtbacka et al. ANNALS OF SURGICAL ONCOLOGY
- The efficacy of anti-PD-1 agents in acral and mucosal melanoma
- (2016) Alexander N. Shoushtari et al. CANCER
- Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies
- (2016) Alain P. Algazi et al. CANCER
- Phase I study of pegylated interferon-alpha-2b as an adjuvant therapy in Japanese patients with malignant melanoma
- (2016) Naoya Yamazaki et al. JOURNAL OF DERMATOLOGY
- Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
- (2016) Paolo A Ascierto et al. LANCET ONCOLOGY
- Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial
- (2016) Jeffrey S Weber et al. LANCET ONCOLOGY
- The use of pembrolizumab for the treatment of metastatic uveal melanoma
- (2016) Lisa A. Kottschade et al. MELANOMA RESEARCH
- Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
- (2016) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma
- (2016) Ioannis Karydis et al. OncoImmunology
- Phase II study of the immune-checkpoint inhibitor ipilimumab plus dacarbazine in Japanese patients with previously untreated, unresectable or metastatic melanoma
- (2015) N. Yamazaki et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma
- (2015) N. Yamazaki et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Genomic Classification of Cutaneous Melanoma
- (2015) Rehan Akbani et al. CELL
- A phase I/Ib study of trametinib (GSK1120212) alone and in combination with gemcitabine in Japanese patients with advanced solid tumors
- (2015) Akiyoshi Kasuga et al. INVESTIGATIONAL NEW DRUGS
- Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
- (2015) Robert H.I. Andtbacka et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients
- (2015) Kaori Sakaizawa et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- Phase I/II study of vemurafenib in patients with unresectable or recurrent melanoma withBRAFV600mutations
- (2015) Naoya Yamazaki et al. JOURNAL OF DERMATOLOGY
- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
- (2015) Georgina V Long et al. LANCET
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
- (2015) Alexander M M Eggermont et al. LANCET ONCOLOGY
- BRAF V600 mutations and pathological features in Japanese melanoma patients
- (2015) Naoya Yamazaki et al. MELANOMA RESEARCH
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Understanding the Biology of Melanoma and Therapeutic Implications
- (2014) Ryan J. Sullivan et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
- (2014) Grant A McArthur et al. LANCET ONCOLOGY
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
- (2014) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
- (2014) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase II Randomized Trial Comparing High-Dose IFN- 2b with Temozolomide Plus Cisplatin as Systemic Adjuvant Therapy for Resected Mucosal Melanoma
- (2013) B. Lian et al. CLINICAL CANCER RESEARCH
- Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin
- (2013) F. Stephen Hodi et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated Interferon Alfa-2b Versus Observation in Resected Stage III Melanoma
- (2012) Alexander M.M. Eggermont et al. JOURNAL OF CLINICAL ONCOLOGY
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
- (2012) Keith T. Flaherty et al. NEW ENGLAND JOURNAL OF MEDICINE
- KIT as a Therapeutic Target in Metastatic Melanoma
- (2011) Richard D. Carvajal JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboringc-KitMutation or Amplification
- (2011) Jun Guo et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Phase II trial of imatinib mesylate in patients with metastatic melanoma
- (2008) K B Kim et al. BRITISH JOURNAL OF CANCER
- Statistical profiles of malignant melanoma and other skin cancers in Japan: 2007 update
- (2008) Kazuyuki Ishihara et al. International Journal of Clinical Oncology
- Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial
- (2008) Alexander MM Eggermont et al. LANCET
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More